Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers (Q36543145)

14 August 2017

1 reference

title

Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers (English)

1 reference

14 August 2017

1 reference

arterial hypertension

1 reference

1

Manu Jain

1 reference

14 August 2017

John Varga

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

11

1 reference

14 August 2017

page(s)

1487-1501

1 reference

Severe restrictive lung disease in systemic sclerosis.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Increased plasma serotonin in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Autoantibodies in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Highlights on endothelins: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Cloning and expression of a cDNA encoding an endothelin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

21 January 2018

Endothelin antagonists

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Bosentan therapy for portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Safety and tolerability of bosentan in adults with Eisenmenger physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Effects of long-term bosentan in children with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Primary pulmonary hypertension. A national prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Endothelin receptor antagonists in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1487

10.1517/14656566.7.11.1487

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference